within Pharmacolibrary.Drugs.ATC.A;

model A10BH05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 1.1666666666666667,
    adminDuration  = 600,
    adminMass      = 0.005,
    adminCount     = 1,
    Vd             = 1.11,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.014166666666666666,
    Tlag           = 15.0
  );

  annotation(Documentation(
    info ="<html><body><p>Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used for the treatment of type 2 diabetes mellitus. It helps to improve glycaemic control by increasing incretin levels, thereby stimulating insulin release and decreasing glucagon secretion. Linagliptin is approved and widely used today for the management of type 2 diabetes.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported for healthy adult subjects (both males and females), after single oral administration.</p><h4>References</h4><ol><li><p>Li, Y, et al., &amp; Wang, X (2022). Pharmacokinetics and Bioequivalence of Single-Oral-Dose Linagliptin: A Randomized, 2-Period Crossover Trial in Chinese Healthy Subjects Under Fasting and Fed Conditions. <i>Clinical pharmacology in drug development</i> 11(10) 1157–1164. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1104&quot;>10.1002/cpdd.1104</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35514254/&quot;>https://pubmed.ncbi.nlm.nih.gov/35514254</a></p></li><li><p>Graefe-Mody, U, et al., &amp; Friedrich, C (2012). Clinical pharmacokinetics and pharmacodynamics of linagliptin. <i>Clinical pharmacokinetics</i> 51(7) 411–427. DOI:<a href=&quot;https://doi.org/10.2165/11630900-000000000-00000&quot;>10.2165/11630900-000000000-00000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22568694/&quot;>https://pubmed.ncbi.nlm.nih.gov/22568694</a></p></li><li><p>Friedrich, C, et al., &amp; Woerle, HJ (2011). Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study. <i>Clinical drug investigation</i> 31(9) 643–653. DOI:<a href=&quot;https://doi.org/10.2165/11590240-000000000-00000&quot;>10.2165/11590240-000000000-00000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21714581/&quot;>https://pubmed.ncbi.nlm.nih.gov/21714581</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A10BH05;
